PDCD1 and neoplasm: Examination of the emergence of acquired resistance in patients with non-small cell lung cancer who initially responded to PD-1 blockade or combined PD-1 and CTLA-4 blockade therapy revealed a decrease in mutation-associated neoantigens in resistant tumors compared with pretreatment tumor samples (61).